Top

European Archives of Oto-Rhino-Laryngology

Published in:

01-02-2020 | Rhinosinusitis | Rhinology

The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data

Authors: Marion San Nicoló, Catalina Högerle, Donata Gellrich, Katharina Eder, Elisabeth Pfrogner, Moritz Gröger

Published in: European Archives of Oto-Rhino-Laryngology | Issue 2/2020

Abstract

Purpose

Aspirin-exacerbated respiratory disease (AERD) is a severe form of chronic rhinosinusitis with nasal polyps (CRSwNP) accompanied by asthma and an aspirin intolerance. The underlying pathomechanism of AERD still remains unclear, recent data suggest a complex inflammatory imbalance. In the present study, we investigated the cytokine patterns in AERD, CRSwNP and healthy control patients. Furthermore, we describe the change in cytokine level in the course of aspirin desensitization (AD) with continuous intake of aspirin.

Methods

The study included a total of 104 participants, 48 healthy controls, 45 patients with nasal polyps and 11 patients with AERD undergoing AD. Nasal secretions were analyzed for IL-1β, IL-4, IL-5, IL-10, IL-12, IL-13, IL-17, THF-α, IFN-γ, eotaxin and ECP using Bio-Plex Human Cytokine Assay and Uni-CAP FEIA. Baseline measurements of cytokine levels were performed in all 104 patients; in patients with AERD, follow-up was performed 1–6 and 6–24 months after the initiation of AD.

Results

Our preliminary results show a T_H2 dominated, eosinophilic milieu in AERD patients, which decreased in the first weeks of AD. However, after 6 months of AD, proinflammatory cytokines show a tendency to increase again. Also, T_H1 as well as T_reg associated cytokine seem to increase over time.

Conclusions

For the first time, the present work shows the cytokine pattern in nasal secretions of AERD patients before and during AD. Further investigation of the complex interaction of inflammatory cytokines during AD might reveal important insights into the disease entity of AERD and open up new horizons for a targeted therapy.

Widal F, Abrami P, Lermoyez J (1987) First complete description of the aspirin idiosyncrasy-asthma-nasal polyposis syndrome (plus urticaria)—1922 (with a note on aspirin desensitization): By F. Widal, P. Abrami, J. Lermoyez. J Asthma 24(5):297–300CrossRef

Samter M, Beers RF Jr (1968) Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 68(5):975–983CrossRef

Laidlaw TM (2019) Clinical updates in aspirin-exacerbated respiratory disease. Allergy Asthma Proc 40(1):4–6CrossRef

Havel M et al (2013) Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad. Eur Arch Otorhinolaryngol 270(2):571–578CrossRef

Tajudeen BA, Schwartz JS, Bosso JV (2017) The role of aspirin desensitization in the management of aspirin-exacerbated respiratory disease. Curr Opin Otolaryngol Head Neck Surg 25(1):30–34CrossRef

Weber R et al (2012) Aspirin desensitization: therapy options in patients with aspirin-exacerbated respiratory disease. HNO 60(4):369–383CrossRef

Szczeklik A et al (2004) Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Curr Opin Pulm Med 10(1):51–56CrossRef

Szczeklik A, Stevenson DD (2003) Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 111(5):913–921 (quiz 922) CrossRef

Stevenson DD, Szczeklik A (2006) Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 118(4):773–786 (quiz 787–8) CrossRef

10.

Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G (1975) Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1(5949):67–69CrossRef

11.

Laidlaw TM, Boyce JA (2013) Pathogenesis of aspirin-exacerbated respiratory disease and reactions. Immunol Allergy Clin North Am 33(2):195–210CrossRef

12.

Kim SD, Cho KS (2018) Samter's triad: state of the art. Clin Exp Otorhinolaryngol 11(2):71–80CrossRef

13.

Cahill KN et al (2016) Impaired E prostanoid2 expression and resistance to prostaglandin E2 in nasal polyp fibroblasts from subjects with aspirin-exacerbated respiratory disease. Am J Respir Cell Mol Biol 54(1):34–40CrossRef

14.

Machado-Carvalho L et al (2016) Altered expression and signalling of EP2 receptor in nasal polyps of AERD patients: role in inflammation and remodelling. Rhinology 54(3):254–265CrossRef

15.

Pezato R et al (2016) Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without aspirin exacerbated respiratory disease. Cytokine 77:157–167CrossRef

16.

Van Zele T et al (2006) Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 61(11):1280–1289CrossRef

17.

Konig K et al (2016) Cytokine patterns in nasal secretion of non-atopic patients distinguish between chronic rhinosinusitis with or without nasal polys. Allergy Asthma Clin Immunol 12:19CrossRef

18.

Bousquet J et al (2007) GINA guidelines on asthma and beyond. Allergy 62(2):102–112CrossRef

19.

Rasp G, Thomas PA, Bujia J (1994) Eosinophil inflammation of the nasal mucosa in allergic and non-allergic rhinitis measured by eosinophil cationic protein levels in native nasal fluid and serum. Clin Exp Allergy 24(12):1151–1156CrossRef

20.

Kramer MF et al (2004) In vitro diagnosis of chronic nasal inflammation. Clin Exp Allergy 34(7):1086–1092CrossRef

21.

Vignali DA (2000) Multiplexed particle-based flow cytometric assays. J Immunol Methods 243(1–2):243–255CrossRef

22.

Klimek L et al (2018) Immunology of chronic rhinosinusitis with nasal polyps as a basis for treatment with biologicals. HNO 67:15–26CrossRef

23.

Amatya N, Garg AV, Gaffen SL (2017) IL-17 Signaling: the Yin and the Yang. Trends Immunol 38(5):310–322CrossRef

24.

Gray T et al (2004) Interleukin-1beta-induced mucin production in human airway epithelium is mediated by cyclooxygenase-2, prostaglandin E2 receptors, and cyclic AMP-protein kinase A signaling. Mol Pharmacol 66(2):337–346CrossRef

25.

Fokkens WJ et al. (2012) European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl, 23:3 p preceding table of contents, 1–298

26.

Bobolea I et al (2018) Aspirin desensitization in aspirin-exacerbated respiratory disease: new insights into the molecular mechanisms. Respir Med 143:39–41CrossRef

27.

Laidlaw TM (2018) Pathogenesis of NSAID-induced reactions in aspirin-exacerbated respiratory disease. World J Otorhinolaryngol Head Neck Surg 4(3):162–168CrossRef

28.

Koennecke M et al (2018) Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities. Allergo J Int 27(2):56–65CrossRef

29.

Aktas A, Kurt E, Gulbas Z (2013) Cytokine expression before and after aspirin desensitization therapy in aspirin-exacerbated respiratory disease. Inflammation 36(6):1553–1559CrossRef

30.

Kong SK et al (2016) Aspirin induces IL-4 production: augmented IL-4 production in aspirin-exacerbated respiratory disease. Exp Mol Med 48(1):e202CrossRef

31.

Sanderson CJ (1992) Interleukin-5, eosinophils, and disease. Blood 79(12):3101–3109CrossRef

32.

Collins PD et al (1995) Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 182(4):1169–1174CrossRef

33.

Stevens WW et al (2015) Cytokines in chronic rhinosinusitis: role in eosinophilia and aspirin-exacerbated respiratory disease. Am J Respir Crit Care Med 192(6):682–694CrossRef

34.

Cho DY et al (2013) Expression of dual oxidases and secreted cytokines in chronic rhinosinusitis. Int Forum Allergy Rhinol 3(5):376–383CrossRef

35.

Steinke JW et al (2014) Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease. J Immunol 193(1):41–47CrossRef

36.

Steinke JW et al (2013) Prominent role of IFN-gamma in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 132(4):856–865.e1–3CrossRef

Title: The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data
Authors: Marion San Nicoló
Catalina Högerle
Donata Gellrich
Katharina Eder
Elisabeth Pfrogner
Moritz Gröger
Publication date: 01-02-2020
Publisher: Springer Berlin Heidelberg
Keywords: Rhinosinusitis
Cytokines
Published in: European Archives of Oto-Rhino-Laryngology / Issue 2/2020
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-019-05704-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2020

Evaluation of a bone groove geometry for fixation of a cochlear implant electrode

Assessment of hearing loss induced by tympanic membrane perforations under blast environment

Intratympanic infliximab is a safe and effective rescue therapy for refractory immune-mediated hearing loss

Author’s reply to letter-to-the-editor

Effects of glove finger- versus lidocaine-soaked nasal packing after endoscopic nasal surgery: a prospective randomized controlled trial

Is the proprioceptive neuromuscular facilitation technique superior to Shaker exercises in swallowing rehabilitation?